Blinatumomab and inotuzumab for B cell precursor acute lymphoblastic leukaemia in children: a retrospective study from the Leukemia Working Group of the Spanish Society of Pediatric Hematology and Oncology (SEHOP)

Blinatumomab and inotuzumab ozogamycin represent promising alternatives to conventional chemotherapy in acute lymphoblastic leukaemia (ALL). We analysed data from 29 children with ALL treated under compassionate use with blinatumomab, inotuzumab or both. The complete remission (CR) rate in a heavily...

Descripción completa

Detalles Bibliográficos
Autores: Fuster JL, Molinos-Quintana A, Fuentes C, Fernández JM, Velasco P, Pascual T, Rives S, Dapena JL, Sisinni L, López-Godino O, Palomo P, Villa-Alcázar M, Bautista F, González-Vicent M, López-Duarte M, García-Morín M, Ramos-Elbal E, Ramírez M
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2020
País:España
Institución:Fundació Sant Joan de Déu
Repositorio:r-FSJD. Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
OAI Identifier:oai:fsjd.fundanetsuite.com:p17630
Acceso en línea:https://fsjd.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=17630
Access Level:acceso abierto
Palabra clave:acute lymphoblastic leukaemia
relapse
children
blinatumomab
inotuzumab
id ES_202bbbb11cb0f7bccf1b76e71f79976f
oai_identifier_str oai:fsjd.fundanetsuite.com:p17630
network_acronym_str ES
network_name_str España
repository_id_str
spelling Blinatumomab and inotuzumab for B cell precursor acute lymphoblastic leukaemia in children: a retrospective study from the Leukemia Working Group of the Spanish Society of Pediatric Hematology and Oncology (SEHOP)Fuster JLMolinos-Quintana AFuentes CFernández JMVelasco PPascual TRives SDapena JLSisinni LLópez-Godino OPalomo PVilla-Alcázar MBautista FGonzález-Vicent MLópez-Duarte MGarcía-Morín MRamos-Elbal ERamírez Macute lymphoblastic leukaemiarelapsechildrenblinatumomabinotuzumabBlinatumomab and inotuzumab ozogamycin represent promising alternatives to conventional chemotherapy in acute lymphoblastic leukaemia (ALL). We analysed data from 29 children with ALL treated under compassionate use with blinatumomab, inotuzumab or both. The complete remission (CR) rate in a heavily pretreated population with overt relapse was 47 center dot 6%. At earlier stages (first/second CR), both antibodies represented a useful tool to reduce minimal residual disease, and/or avoid further toxic chemotherapy until stem cell transplantation. Six patients developed grade 3 reversible non-haematological toxicity. The 12-month overall survival and event-free survival rates were 50 center dot 8 +/- 26 center dot 4% and 38 center dot 9 +/- 25 center dot 3% with blinatumomab, 45 center dot 8 +/- 26% and 27 center dot 5 +/- 25% with inotuzumab.WILEY2020info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://fsjd.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=17630BRITISH JOURNAL OF HAEMATOLOGYISSN: 00071048ISSNe: 13652141reponame:r-FSJD. Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déuinstname:Fundació Sant Joan de DéuInglésinfo:eu-repo/semantics/openAccessoai:fsjd.fundanetsuite.com:p176302026-05-27T12:37:41Z
dc.title.none.fl_str_mv Blinatumomab and inotuzumab for B cell precursor acute lymphoblastic leukaemia in children: a retrospective study from the Leukemia Working Group of the Spanish Society of Pediatric Hematology and Oncology (SEHOP)
title Blinatumomab and inotuzumab for B cell precursor acute lymphoblastic leukaemia in children: a retrospective study from the Leukemia Working Group of the Spanish Society of Pediatric Hematology and Oncology (SEHOP)
spellingShingle Blinatumomab and inotuzumab for B cell precursor acute lymphoblastic leukaemia in children: a retrospective study from the Leukemia Working Group of the Spanish Society of Pediatric Hematology and Oncology (SEHOP)
Fuster JL
acute lymphoblastic leukaemia
relapse
children
blinatumomab
inotuzumab
title_short Blinatumomab and inotuzumab for B cell precursor acute lymphoblastic leukaemia in children: a retrospective study from the Leukemia Working Group of the Spanish Society of Pediatric Hematology and Oncology (SEHOP)
title_full Blinatumomab and inotuzumab for B cell precursor acute lymphoblastic leukaemia in children: a retrospective study from the Leukemia Working Group of the Spanish Society of Pediatric Hematology and Oncology (SEHOP)
title_fullStr Blinatumomab and inotuzumab for B cell precursor acute lymphoblastic leukaemia in children: a retrospective study from the Leukemia Working Group of the Spanish Society of Pediatric Hematology and Oncology (SEHOP)
title_full_unstemmed Blinatumomab and inotuzumab for B cell precursor acute lymphoblastic leukaemia in children: a retrospective study from the Leukemia Working Group of the Spanish Society of Pediatric Hematology and Oncology (SEHOP)
title_sort Blinatumomab and inotuzumab for B cell precursor acute lymphoblastic leukaemia in children: a retrospective study from the Leukemia Working Group of the Spanish Society of Pediatric Hematology and Oncology (SEHOP)
dc.creator.none.fl_str_mv Fuster JL
Molinos-Quintana A
Fuentes C
Fernández JM
Velasco P
Pascual T
Rives S
Dapena JL
Sisinni L
López-Godino O
Palomo P
Villa-Alcázar M
Bautista F
González-Vicent M
López-Duarte M
García-Morín M
Ramos-Elbal E
Ramírez M
author Fuster JL
author_facet Fuster JL
Molinos-Quintana A
Fuentes C
Fernández JM
Velasco P
Pascual T
Rives S
Dapena JL
Sisinni L
López-Godino O
Palomo P
Villa-Alcázar M
Bautista F
González-Vicent M
López-Duarte M
García-Morín M
Ramos-Elbal E
Ramírez M
author_role author
author2 Molinos-Quintana A
Fuentes C
Fernández JM
Velasco P
Pascual T
Rives S
Dapena JL
Sisinni L
López-Godino O
Palomo P
Villa-Alcázar M
Bautista F
González-Vicent M
López-Duarte M
García-Morín M
Ramos-Elbal E
Ramírez M
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv acute lymphoblastic leukaemia
relapse
children
blinatumomab
inotuzumab
topic acute lymphoblastic leukaemia
relapse
children
blinatumomab
inotuzumab
description Blinatumomab and inotuzumab ozogamycin represent promising alternatives to conventional chemotherapy in acute lymphoblastic leukaemia (ALL). We analysed data from 29 children with ALL treated under compassionate use with blinatumomab, inotuzumab or both. The complete remission (CR) rate in a heavily pretreated population with overt relapse was 47 center dot 6%. At earlier stages (first/second CR), both antibodies represented a useful tool to reduce minimal residual disease, and/or avoid further toxic chemotherapy until stem cell transplantation. Six patients developed grade 3 reversible non-haematological toxicity. The 12-month overall survival and event-free survival rates were 50 center dot 8 +/- 26 center dot 4% and 38 center dot 9 +/- 25 center dot 3% with blinatumomab, 45 center dot 8 +/- 26% and 27 center dot 5 +/- 25% with inotuzumab.
publishDate 2020
dc.date.none.fl_str_mv 2020
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://fsjd.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=17630
url https://fsjd.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=17630
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv WILEY
publisher.none.fl_str_mv WILEY
dc.source.none.fl_str_mv BRITISH JOURNAL OF HAEMATOLOGY
ISSN: 00071048
ISSNe: 13652141
reponame:r-FSJD. Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
instname:Fundació Sant Joan de Déu
instname_str Fundació Sant Joan de Déu
reponame_str r-FSJD. Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
collection r-FSJD. Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869404443450015744
score 15,811543

Similares en LA Referencia